GordonMD Global Investments LP bought 5,517,000 shares of Pyxis Oncology, Inc. on Oct 1, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
10% owner
10%
Filed Oct 2, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
—Shares × reported price
Shares traded
5,517,000Common Stock, par value $0.001 per share ("Common Stock")
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
55.03%This security and ownership context
Holdings after
15,541,909Indirect · See footnote
Trade date
Oct 1, 2026Buy
Filed
Oct 2, 2026, 8:35 AM ET1-day reporting delay
Accession
0000919574-26-006609Code P · Transaction 233662
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 10,024,909 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Oct 1, 2026Buy7,546,766——Trade 233663
2 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

PYXS price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
PYXS · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +61%1w ago +36%1d ago +8.9%
Returns since7d −5.6%30d −15%90d180d1y

Footnotes in full

F1: The securities to which this filing relates are held directly by GordonMD Long Biased Master Fund LP (the "Master Fund") to which GordonMD Global Investments LP (the "Investment Manager") serves as investment manager. Craig D. Gordon ("Mr. Gordon") is the managing member of GordonMD Long Biased GP LLC (the "GP"), the general partner of the Master Fund. Each of the Master Fund, the GP and Mr. Gordon disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. F2: The combined public offering price for each share of common stock and accompanying Common Stock Purchase Warrant is $2.90. F3: Exercise price of $3.5, subject to adjustments as set forth in the Common Stock Purchase Warrant. F4: The Common Stock Purchase Warrant will not be exercisable unless and until (i) the issuer's stockholders approve an amendment to the issuer's amended and restated certificate of incorporation to increase the number of authorized shares of Common Stock (the "Charter Amendment") and (ii) the Charter Amendment is filed with, and becomes effective under the laws of, the State of Delaware (the date on which the Charter Amendment becomes effective, the "Charter Amendment Effective Date"). F5: The Common Stock Purchase Warrant will expire on the earlier of (i) the fifth anniversary of the Charter Amendment Effective Date and (ii) the 30th calendar day following the later of the Charter Amendment Effective Date and the date on which the issuer publicly discloses the results of the overall survival analysis for its Phase 1 monotherapy study of MICVO in second-line and later recurrent or metastatic head and neck squamous cell carcinoma.